[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346398-105":59,"doc-detail-346398-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","developing-an-antibody-drug-encapsulation-nanoagent-targeting-her2-for-cancer-treatment","Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment","","HER2 is overexpressed in 15–20% of breast cancer and other malignancies, making it a central target for Trastuzumab (Tr)-based antibody drug conjugates (ADCs). Traditional ADCs are limited by in vivo instability, inefficient payload release, and complex manufacturing. This study develops Tr-ACT2, a single protein encapsulation antibody drug encapsulation nanoagent, to improve stability, delivery, and antitumor performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/developing-an-antibody-drug-encapsulation-nanoagent-targeting-her2-for-cancer-treatment/346398/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/developing-an-antibody-drug-encapsulation-nanoagent-targeting-her2-for-cancer-treatment/346398.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HER2 a key target for cancer therapy?","Question",{"text":112,"@type":113},"HER2 is overexpressed in about 15–20% of breast cancers and is also implicated across multiple cancer types, supporting its use for targeted treatments.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problems do traditional HER2 ADCs face?",{"text":117,"@type":113},"They often suffer from limited in vivo stability, inefficient drug release, and complicated manufacturing processes.",{"name":119,"@type":110,"acceptedAnswer":120},"How does Tr-ACT2 differ from conventional antibody-drug conjugates?",{"text":121,"@type":113},"Tr-ACT2 encapsulates two actinomycin D (ACT) molecules within the Tr protein without chemical conjugation and linkers, aiming to improve delivery and therapeutic activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346398,1790198020,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Li et al. Journal of Translational Medicine (2026) 24:147  \n[https://doi.org/10.1186/s12967-025-07450-x](https://doi.org/10.1186/s12967-025-07450-x)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nDeveloping an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment  \nLinrong Li 1,2, Ru Yao 1, Yan Liu2, Nelyda Gonzalez Almeyda3, Qiang Sun 1, Faqing Huang4, Leslie Wang5, Kinsley Wang5, James Turkson6, Lali Medina-Kauwe3, Armando Giuliano2, Changjun Yu5,7* and Xiaojiang Cui2*  \nAbstract  \nBackground Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15–20% of breast cancer and some other cancers. Trastuzumab (Tr)-based antibody drug conjugates (ADCs) have emerged as a new class of antiHER2 therapies. However, traditional ADCs face challenges including limited in vivo stability, inefficient drug release, and manufacturing complexities.  \nMethods We developed Tr-ACT2, a first-in-class antibody drug encapsulation nanoagent, using single protein encapsulation technology. Tr-ACT2 was characterized by UV absorbance/fluorescence emission spectroscopy, membrane dialysis, particle size distribution, and molecular docking studies. In vitro cellular uptake and cytotoxicity were evaluated in breast and lung cancer cell lines using cell viability assays, western blotting, apoptosis assays, and immunofluorescence. In vivo toxicity was assessed using the A549 xenograft mouse model treated with Tr-ACT2 oririnotecan.  \nResults As a potential antibody-encapsulated drug (AED), Tr-ACT2 features each Tr protein encapsulating two actinomycin D (ACT) molecules without chemical conjugation and linkers. Tr-ACT2 exhibited time-dependent internal ization into breast and lung cancer cells with various HER2 expression levels. It led to inhibition of cell growth, induction of apoptosis, and reduction of Akt activation. Notably, Tr-ACT2’s cytotoxic activity appeared to be independent of HER2 expression levels. In a human lung cancer xenograft mouse model, intravenous administration of Tr-ACT2 demonstrated a significant anticancer therapeutic efficacy.  \nConclusions These findings support further evaluation of Tr-ACT2 for the treatment of human cancers. The AED approach may be broadly applicable to other antibodies and chemotherapeutic agents, potentially opening a new avenue for developing targeted anticancer therapies.  \nKeywords Actinomycin D, Antibody encapsulated drug, Breast cancer, Trastuzumab, Single protein encapsulation, Tr-ACT2  \n*Correspondence: Changjun Yu [cjyu@caltech.edu](cjyu@caltech.edu)[ ](cjyu@caltech.edu)Xiaojiang Cui [xiaojiang.cui@cshs.org](xiaojiang.cui@cshs.org)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nLi et al. Journal of Translational Medicine (2026) 24:147  \nIntroduction  \nHuman epidermal growth factor receptor 2 (HER2) is atransmembrane glycoprotein with intracellular tyrosine kinase activ","cbCaic3Q8g8Kd0cN","https://ap.wps.com/l/cbCaic3Q8g8Kd0cN","pdf",6616737,13,"English","# Abstract\n# Background\n# Methods\n## Characterization\n## In vitro evaluation\n## In vivo evaluation\n# Results\n# Conclusions","[{\"question\":\"Why is HER2 a key target for cancer therapy?\",\"answer\":\"HER2 is overexpressed in about 15–20% of breast cancers and is also implicated across multiple cancer types, supporting its use for targeted treatments.\"},{\"question\":\"What problems do traditional HER2 ADCs face?\",\"answer\":\"They often suffer from limited in vivo stability, inefficient drug release, and complicated manufacturing processes.\"},{\"question\":\"How does Tr-ACT2 differ from conventional antibody-drug conjugates?\",\"answer\":\"Tr-ACT2 encapsulates two actinomycin D (ACT) molecules within the Tr protein without chemical conjugation and linkers, aiming to improve delivery and therapeutic activity.\"}]","Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment | PDF",1790061269,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18c70260f009bb9a26a8de2a8d11db44.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3386fb0b8870252f959b23775af1dbf9.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c61679eefca362cb8ceffd22b6e26dfa.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05d1123dba13541459975f78f98299e.webp",980,1306]